INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Alfred Hospital
Melbourne, AustraliaPublicaciones en colaboración con investigadores/as de Alfred Hospital (7)
2023
-
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Blood, Vol. 141, Núm. 2, pp. 156-167
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
2014
-
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600
2007
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 357, Núm. 21, pp. 2123-2132
2002
-
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia
Blood, Vol. 100, Núm. 12, pp. 3877-3886